Evofem Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue $0.9 million, net income $5.5 million, EPS $(0.04) per basic and diluted share.
“For the three months ended March 31, 2026, net sales were $0.9 million”
Evofem Biosciences, Inc. — fact timeline
Source-grounded facts extracted from Evofem Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Evofem Biosciences, Inc. entered into Distributorship Agreement with Clovis Davis Pharmaceuticals, LLC. (effective 2026-04-24).
“On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.”
Evofem Biosciences, Inc. amended Fourth Amendment with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant) (effective 2026-04-10).
“On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).”
Evofem Biosciences, Inc. terminated Termination Agreement with Windtree Therapeutics, Inc. (effective 2026-03-13).
“the Company and Windtree entered into a Termination Agreement (the “Termination Agreement”) pursuant to which the parties mutually consented to the termination of the Agreement, effective as of such date.”
Evofem Biosciences, Inc. reported the three months ended December 31, 2025 results: revenue $9.6 million, net income $2.8 million, EPS $0.02 per basic and $0.00 per diluted share.
“For the three months ended December 31, 2025, net sales were $9.6 million, versus $7.1 million in the prior year period.”
Evofem Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $20.2 million, net income $0.3 million, EPS $0.00 per basic and diluted share.
“or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: ● Achieved record net sales of $20.2 million in 2025 — Evofem’s fifth consecutive year of net sales growth — mainly driven by sales of PHEXX® (lactic acid, citric acid, and potassium bitartrate), our hormone-free, on”
Evofem Biosciences, Inc.: Stockholders approved a resolution to amend the Certificate of Incorporation to effect a one-time reverse stock split of Common Stock at a ratio between 1-for-500 and 1-for-1,500, at any time before November 26, 2026 (effective 2026-11-26).
“At the Annual Meeting, the Company’s stockholders approved a resolution as previously approved by the Company’s Board of Directors (“Board”) to amend the Company’s existing Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a one-time reverse stock split of the Company’s Common Stock, to effectuate a reverse stock split of the outstanding shares of the Company’s Common Stock by a ratio of not less than 1-for-500 and not more than 1-for-1,500 at any time before November 26, 2026.”
Evofem Biosciences, Inc.: Filed Certificate of Designations creating Series G-1 Preferred Stock, amending Articles of Incorporation (effective 2025-08-22).
“On August 22, 2025 the Company filed the Certificate of Designations creating the Series G-1 Preferred Stock.”
Evofem Biosciences, Inc. received a otc deficiency notice notice regarding minimum bid price.
“January 6, 2025, Evofem Biosciences, Inc. (the “Company”) received a written notice (the “OTC Notice”) from the OTC Markets Group (“OTC”) notifying the Company that, because the closing bid price for the Company’s common stock was below $0.01 per share for 30 consecutive calendar days, the Company is not currently in compliance with the minimum bid price requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in the OTCQB listing standards, section 2.3 (the “Minimum Bid Price Requirement”). The OTC Notice has no immediate effect on the listing of the Company’s common”
Evofem Biosciences, Inc. received a otc deficiency notice notice regarding minimum bid price.
“January 6, 2025, Evofem Biosciences, Inc. (the “Company”) received a written notice (the “OTC Notice”) from the OTC Markets Group (“OTC”) notifying the Company that, because the closing bid price for the Company’s common”
Evofem Biosciences, Inc. reported the three months ended March 31, 2024 results: revenue $3.6 million, net income loss from operations improved to $2.8 million.
“15.4 million beneficiaries. Effective July 1, 2024, Evofem will pay a 7.4% lower rebate to Medi-Cal on Phexxi prescriptions dispensed to its beneficiaries. ● Net sales were $3.6 million for the first quarter of 2024, reflecting anticipated cyclical softness following the wholesale acquisition cost (WAC) increase on January 1, 2024, and the impact of the”
Evofem Biosciences, Inc. amended Merger Agreement with Aditxt, Inc. valued at Reinstated and amended Merger Agreement via Fourth Amendment, including $1,000,000 initial payment, (effective 2024-05-02).
“On May 2, 2024, the Company, the Merger Sub and Aditxt entered into the Reinstatement and Fourth Amendment to the Merger Agreement (the "Fourth Amendment") in order to waive and amend, among other things, the several provisions listed below.”
Evofem Biosciences, Inc. terminated Merger Agreement with Aditxt, Inc. valued at Company terminated Merger Agreement effective April 26, 2024 in accordance with Section 8.1(f) of th (effective 2024-04-26).
“On April 26, 2024, the Company delivered a termination notice to Aditxt notifying it that the Company was exercising its right to terminate the Merger Agreement effective April 26, 2024 (the "Termination Notice"), in accordance with Section 8.1(f) of the Merger Agreement, as revised in the third amendment to the Merger Agreement, made on February 29, 2024.”
Evofem Biosciences, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million.
“For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.”
Evofem Biosciences, Inc. reported year ended December 31, 2023 results: revenue $18.2 million.
“For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.”
Evofem Biosciences, Inc. entered into December Assignment Agreement with Aditxt, Inc. and certain holders of Company senior indebtedness notes (effective 2023-12-11).
“Aditxt entered into an assignment agreement, dated December 11, 2023 (the “December Assignment Agreement”) pursuant to which Aditxt and certain holders of Company senior indebtedness notes (the “Holders”) assigned their respective notes to Aditxt in consideration for the issuance, by Aditxt, of (i) an aggregate principal amount of $5.0 million in secured notes of the Company due on January 2, 2024 (the “January 2024 Secured Notes”), (ii) an aggregate principal amount of $8.0 million in secured notes of the Company due on September 30, 2024 (the “September 2024 Secured Notes”), (iii) an aggregate principal amount of $5.0 million in ten-year unsecured notes (the “Unsecured Notes”), and (iv) payment of $154,480 in respect of net sales of Phexxi in respect of the calendar quarter ended September 30, 2023 (the payment, together with the September 2024 Notes, the December 2023 Notes and the Unsecured Notes, as may have been amended from time to time, the “Notes”).”
Evofem Biosciences, Inc. entered into Agreement and Plan of Merger with Aditxt, Inc. and Adicure, Inc. (effective 2023-12-11).
“on December 11, 2023 the Company, Aditxt, Inc., a Delaware Corporation (“Aditxt”) and Adicure, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), whereby the Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the “Merger”).”
Evofem Biosciences, Inc. reported fiscal year ended December 31, 2023 results: revenue preliminary net product sales in the range of $18.1 to $18.3 million.
“contraceptive gel, and the Company’s lowest total operating expenses since becoming a commercial stage company in 2020. ● Achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023. ● Company reached a key milestone”
Evofem Biosciences, Inc. amended Second Amendment to the Agreement and Plan of Merger with Aditxt, Inc. valued at amendment to change the date of the Parent Loan to February 29, 2024, termination date for failure t (effective 2024-01-30).
“On January 30, 2024, the Company, Parent and Merger Sub entered into the second amendment to the Merger Agreement (the “Second Amendment”) to amend (i) the date of the Parent Loan (as defined in the Merger Agreement) to the Company to be February 29, 2024, (ii) to change the date by which the Company may terminate the Merger Agreement for failure to receive the Loan from Parent to be February 29, 2024, and (iii) to change the filing date for the Joint Proxy Statement (as defined in the Merger Agreement) to April 1, 2024.”
Evofem Biosciences, Inc. amended Agreement and Plan of Merger with Aditxt, Inc., Adicure, Inc. (effective 2024-01-08).
“On January 8, 2024, the Company, Aditxt and Merger Sub entered into the first amendment to the Merger Agreement (the “First Amendment”), to change the filing date for the Joint Proxy Statement (as defined in the Merger Agreement) to February 14, 2024.”
Evofem Biosciences, Inc. entered into Rights Exchange Agreement with Holders of previously issued Securities valued at Exchange of Original Rights for New Rights (effective 2023-12-21).
“On December 21, 2023, Evofem Biosciences, Inc. (the “Company”) entered into the following agreements with holders (each a “Holder”) of certain of the Company’s previously issued Securities (as defined below) (i) a waiver and rights exchange agreement (the “Rights Exchange Agreements")”
Evofem Biosciences, Inc.: Filed a Certificate of Designations creating Series F-1 Preferred Stock, specifying rights, preferences, and privileges (effective 2023-12-11).
“On December 11, 2023 the Company filed a Certificate of Designations creating a new series of preferred stock designated as "Series F-1 Preferred Stock."”
Evofem Biosciences, Inc. entered into Merger Agreement with Aditxt, Inc. and Adicure, Inc. (effective 2023-12-11).
“On December 11, 2023, Evofem Biosciences, Inc. (“Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Aditxt, Inc., a Delaware corporation (“Parent”), Adicure, Inc., a Delaware corporation and a wholly-owned Subsidiary of parent (“Merger Sub”), pursuant to which, and on the terms and subject to the conditions thereof, Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”).”
Evofem Biosciences, Inc. amended Restructuring Agreements with certain holders of the Company's previously issued securities (effective 2023-12-01).
“On December 1, 2023, Evofem Biosciences, Inc. (the “Company”) entered into agreements with the holders (each a “Holder”) of certain of the Company’s previously issued securities (collectively, the “Restructuring Agreements”).”
Evofem Biosciences, Inc. reported third quarter ended September 30, 2023 results: revenue $5.1 million in net product sales, net income net income was $66.0 million, EPS $15.34 per basic and $0.10 per diluted share.
“November 14, 2023 —Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: ● $5.1 million in net product sales of Phexxi ® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023. ○ More than 82% of”
Evofem Biosciences, Inc. reported financial results for three and nine months ended September 30, 2023.
“On November 14, 2023, Evofem Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.”
Evofem Biosciences, Inc. reported the third quarter of 2023 results: revenue $5.0 to $5.2 million.
“gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives. ● Phexxi net product sales expected to be $5.0 to $5.2 million for the third quarter of 2023. ● Evofem remains on track to deliver its third consecutive year of net product sales growth. ● Selling and marketing expenses were”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at Aggregate principal amount of $2,884,615 of senior subordinate convertible notes, Series A Warrants (effective 2023-09-27).
“On September 27, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $2,884,615 (the “ Notes ”), warrants to purchase an aggregate of 22,189,349 shares (the “ Series A Warrants ”) of common stock the Company, par value $0.0001 (the “Common Stock”), and prepaid warrants to purchase an aggregate of 4,807,692 shares of Common Stock (the “ Series B Warrants ,” and, together with the Series A Warrants, the “ Warrants ”) (collectively, the “ Offering ”).”
Evofem Biosciences, Inc.: Increased total authorized common shares to 3,000,000,000 (effective 2023-09-15).
“the Company’s stockholders approved a resolution to amend the Company’s existing Amended and Restated Certificate of Incorporation (“Certificate”)”
Evofem Biosciences, Inc. shareholders approved Ratification of the appointment of BPM LLP as the Company's Independent Registered Public Accounting firm for the year ending December 31, 2023 at the 2023-09-14 meeting.
“Proposal 4 Ratification of the appointment of BPM LLP as the Company’s Independent Registered Public Accounting firm for the year ending December 31, 2023. Votes For Votes Against Votes Withheld Broker Non-Vote 4,943,298 34,100 34,088 -”
Evofem Biosciences, Inc. shareholders approved Approval of the amendment to the Company's Restated Certificate to authorize an increase in the total number of common shares authorized to 3,000,000,000 at the 2023-09-14 meeting.
“Proposal 3 Approval of the amendment unanimously approved by the Company’s board of directors to the Company’s Restated Certificate to authorize an increase in the total number of common shares authorized to 3,000,000,000. Votes For Votes Against Votes Withheld Broker Non-Vote 4,722,280 271,079 18,127 -”
Evofem Biosciences, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of our named executive officers at the 2023-09-14 meeting.
“Proposal 2 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. Votes For Votes Against Votes Withheld Broker Non-Vote 4,754,413 185,842 71,231 -”
Evofem Biosciences, Inc. shareholders approved Election of Saundra Pelletier as a Class III director at the 2023-09-14 meeting.
“Proposal 1 Election of the following nominee as a Class III director of the company, to serve a three-year term until the 2026 Annual Meeting of Stockholders and until her successor is duly elected and qualified. Votes For Votes Against Votes Withheld Broker Non-Vote Saundra Pelletier 4,821,109 - 190,377 -”
Evofem Biosciences, Inc. amended Fourth Amendment with certain institutional investors (effective 2023-09-08).
“On September 8, 2023 (“Effective Date”), Evofem Biosciences, Inc. (the “Company”), certain institutional investors (the “Purchasers”) and Baker Bros. Advisors LP as their designated agent (the “Designated Agent”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase and Security Agreement by and among the Company, the Purchasers and the Designated Agent, dated as of April 23, 2020 (the “Agreement”), as amended, pursuant to which the Purchasers purchased certain convertible promissory notes (the “Notes”).”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement.
“.01 Material Definitive Agreement Securities Purchase Agreement. Notes The Notes will be the senior subordinate obligations of the Company and not the financial obligations of our subsidiaries.”
Evofem Biosciences, Inc. reported the three and six months ended June 30, 2023 results: revenue $2.5 million, net income $8.6 million, EPS $(5.43) per share. Guidance reaffirmed.
“and we remain on track to deliver our third consecutive year of Phexxi net sales growth.” Financial Results For the three months ended June 30, 2023, net product sales were $2.5 million compared to $6.0 million in the prior year period. The 59% decrease was primarily due to lower Phexxi ® (lactic acid, citric acid and potassium bitartrate) ex-factory unit”
Evofem Biosciences, Inc.: Filed Certificate of Designations creating Series E-1 Preferred Stock, part of Amended and Restated Articles of Incorporation (effective 2023-08-07).
“On August 7, 2023 the Company filed the Certificate of Designations creating the Series E-1 Preferred Stock. The Certificate of Designations, which forms a part of the Company’s Amended and Restated Articles of Incorporation, specifies the terms of the Series E-1 Preferred Stock.”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at Notes in aggregate original principal amount of $1,000,000 and Warrants to purchase 799,999 shares o (effective 2023-08-04).
“On August 4, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,000,000 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 799,999 shares of Common Stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering ”).”
Evofem Biosciences, Inc.: Amended and restated bylaws to remove requirement for Board consent to reschedule annual meeting and reduce quorum from a majority to one-third (effective 2023-07-11).
“On July 11, 2023, the board of directors the (“Board”) of Evofem Biosciences, Inc. (the “Company”), adopted and approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”) in order to change, among other things: ● Section 2, removing requirement for Board Consent to reschedule annual meeting ● Section 3, so the proportion of shares present required to constitute a quorum at a meeting of stockholders, from a majority to one-third of the outstanding shares of stock entitled to vote, as permitted under § 216 of the Delaware General Corporation Law.”
Evofem Biosciences, Inc. engaged BPM LLP as its auditor.
“On July 11, 2023, the Company appointed BPM LLP ("BPM") as the Company's new independent registered public accounting firm effective as of July 11, 2023.”
Evofem Biosciences, Inc. dismissed Deloitte & Touche LLP as its auditor.
“the Audit Committee recommended, and the Board approved the dismissal of Deloitte & Touche LLP ("Deloitte"), as the Company's independent registered public accounting firm, on July 11, 2023.”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $1,500,000 (effective 2023-07-03).
“On July 3, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”) with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,500,000”
Evofem Biosciences, Inc. reported first quarter of 2023 results: revenue $5.8 million, net income $(2.4) million, EPS $(1.85) per share. Guidance reaffirmed.
“contraceptive gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) . Highlights for and since the quarter include: ● Increased Phexxi net product sales 37% to $5.8 million. ● Reduced total operating expenses 72% to $9.4 million. ○ Implemented measures in March 2023 to further decrease operating expenses. ● Loss from operations decreased 88% to”
Evofem Biosciences, Inc. reported the first quarter of 2023 results: revenue approximately $5.8 million. Guidance reaffirmed.
“hormone-free prescription contraceptive gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) . ● Increased Phexxi net product sales more than 35% to approximately $5.8 million in Q1 2023, versus $4.3 million in Q1 2022. ● Reduced total operating expenses more than 70% to approximately $9.4 million, versus $33.2 million in Q1 2022. ● Decreased loss”
Evofem Biosciences, Inc.: Amended certificate of incorporation to effect a 1-for-125 reverse stock split, effective May 18, 2023 (effective 2023-05-18).
“On May 17, 2023, the Company filed with the Secretary of State of the State of Delaware a Certificate of Correction (the “Certificate of Correction”) to change the effective time of the Reverse Stock Split from May 3, 2023 to May 18, 2023. As a result, the Reverse Stock Split will become effective upon the open of trading on the OTC Venture Market on May 18, 2023 (the “Effective Time”).”
Evofem Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $16.8 million, net income $(78.0) million, or $(1.34) per share, EPS $(1.34) per share.
“citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022. Highlights include: ● Increased Phexxi net product sales 104% to $16.8 million in 2022. ● Gained Phexxi coverage for more than 22.1 million new lives since January 1, 2023. ● More than 80% of Phexxi claims are now being approved (as of February 2023, the”
Ivy Zhang was appointed as Chief Financial Officer and Secretary at Evofem Biosciences, Inc..
“Ivy Zhang was appointed as the Chief Financial Officer and Secretary of the Company, effective immediately.”
Albert Altro was terminated as interim Chief Financial Officer at Evofem Biosciences, Inc..
“Albert Altro’s appointment as the Company’s interim Chief Financial Officer terminated, effective immediately.”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $769,230.76 (effective 2023-04-05).
“On April 5, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”) entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $769,230.76”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with Investors valued at Senior subordinate convertible notes due in aggregate original principal amount of $769,230.76, inte (effective 2023-04-05).
“On April 5, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $769,230.76 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 26,923,077 shares of common stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.